QuidelOrtho (NASDAQ:QDEL) Issues Earnings Results

QuidelOrtho (NASDAQ:QDEL) announced its quarterly earnings data on Tuesday. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.13, FiscalAI reports. The firm had revenue of $618.90 million during the quarter, compared to analysts’ expectations of $627.83 million. QuidelOrtho had a positive return on equity of 3.22% and a negative net margin of 14.24%. The company’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.80 EPS.

Here are the key takeaways from QuidelOrtho’s conference call:

• China and respiratory weakness drove the decline: Q3 revenue fell 12% to $619 million, with China down 45% and Point of Care down 27% as respiratory revenue declined 39%. Management expects China to fall from about 8% of revenue in 2026 to 4%–5% in 2027 amid destocking, pricing pressure, and competition.
• Core businesses continued to grow outside China: Labs revenue rose 4% and immunohematology revenue rose 3%, supported by demand across key markets and the company’s installed base.
• A new restructuring program targets more than $80 million in annual savings in 2027, which management says should more than offset near-term China headwinds. The program will incur $30 million–$35 million in restructuring charges, with most of the cash outflow expected in Q4 2026.
• Guidance and leverage reflect continued pressure: The company narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects adjusted EBITDA of $540 million–$545 million and adjusted EPS of $0.65–$0.70. Free cash flow was approximately break-even in Q3, while net leverage rose to 4.5x from 4.3x in Q2.

QuidelOrtho Stock Down 16.7%

Shares of NASDAQ:QDEL opened at $10.70 on Friday. The business’s 50 day simple moving average is $12.59 and its two-hundred day simple moving average is $15.96. The firm has a market cap of $734.13 million, a P/E ratio of 12.44 and a beta of 0.77. QuidelOrtho has a 52-week low of $9.92 and a 52-week high of $35.58. The company has a debt-to-equity ratio of 1.40, a quick ratio of 0.76 and a current ratio of 1.36.

Wall Street Analyst Weigh In

QDEL has been the subject of a number of research analyst reports. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Friday, October 9th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $13.62.

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.